Last reviewed · How we verify
AIDS 347: IL-6 Blockade in Treated HIV Infection
The study is a phase I/II, double-blind, placebo-controlled, randomized cross-over clinical trial of tocilizumab (TCZ) or placebo in HIV-infected subjects receiving antiretroviral therapy with suppressed viral replication and CD4+ T cell count ≥350 and ≤1,000 cells/mm3)
Details
| Lead sponsor | Case Western Reserve University |
|---|---|
| Phase | Phase 1/Phase 2 |
| Status | COMPLETED |
| Enrolment | 34 |
| Start date | 2014-08 |
| Completion | 2017-09-11 |
Conditions
- HIV Infections
Interventions
- tocilizumab
- Placebo
Primary outcomes
- Number of Grade 2 or Greater AEs — 30 weeks
The number and percentage of participants experiencing at least one grade ≥2 clinical or laboratory adverse event related to study treatment during each period (0 to 10 weeks for Period 1 or 20 to 30 weeks for Period 2).
Countries
United States